105 related articles for article (PubMed ID: 30032787)
1. SATB1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas.
Poglio S; Merlio JP
J Invest Dermatol; 2018 Aug; 138(8):1694-1696. PubMed ID: 30032787
[TBL] [Abstract][Full Text] [Related]
2. SATB1 in Malignant T Cells.
Fredholm S; Willerslev-Olsen A; Met Ö; Kubat L; Gluud M; Mathiasen SL; Friese C; Blümel E; Petersen DL; Hu T; Nastasi C; Lindahl LM; Buus TB; Krejsgaard T; Wasik MA; Kopp KL; Koralov SB; Persson JL; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Becker JC; Ødum N
J Invest Dermatol; 2018 Aug; 138(8):1805-1815. PubMed ID: 29751003
[TBL] [Abstract][Full Text] [Related]
3. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas.
Grzanka A; Grzanka D; Gagat M; Tadrowski T; Sokołowska-Wojdyło M; Marszałek A; Placek W
Pol J Pathol; 2012 Jun; 63(2):101-5. PubMed ID: 22864778
[TBL] [Abstract][Full Text] [Related]
4. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.
Harro CM; Perez-Sanz J; Costich TL; Payne KK; Anadon CM; Chaurio RA; Biswas S; Mandal G; Rigolizzo KE; Sprenger KB; Mine JA; Showe LC; Yu X; Liu K; Rodriguez PC; Pinilla-Ibarz J; Sokol L; Conejo-Garcia JR
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33270606
[TBL] [Abstract][Full Text] [Related]
5. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.
Wang Y; Gu X; Zhang G; Wang L; Wang T; Zhao Y; Zhang X; Zhou Y; Kadin M; Tu P
Blood; 2014 May; 123(22):3452-61. PubMed ID: 24747435
[TBL] [Abstract][Full Text] [Related]
6. Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma.
Grzanka D; Gagat M; Izdebska M; Marszałek A
Oncol Rep; 2015 Jan; 33(1):250-66. PubMed ID: 25384658
[TBL] [Abstract][Full Text] [Related]
7. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
[TBL] [Abstract][Full Text] [Related]
8. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Bieniek A; Dziegiel P
Anticancer Res; 2016 Jan; 36(1):189-97. PubMed ID: 26722043
[TBL] [Abstract][Full Text] [Related]
9. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
10. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development.
Alvarez JD; Yasui DH; Niida H; Joh T; Loh DY; Kohwi-Shigematsu T
Genes Dev; 2000 Mar; 14(5):521-35. PubMed ID: 10716941
[TBL] [Abstract][Full Text] [Related]
11. Special AT-rich sequence binding protein 1 is required for maintenance of T cell receptor responsiveness and development of experimental autoimmune encephalomyelitis.
Akiba Y; Kuwabara T; Mukozu T; Mikami T; Kondo M
Microbiol Immunol; 2018 Apr; 62(4):255-268. PubMed ID: 29388727
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
13. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas.
Merrill ED; Agbay R; Miranda RN; Aung PP; Tetzlaff MT; Young KH; Curry JL; Nagarajan P; Ivan D; Prieto VG; Medeiros LJ; Duvic M; Torres-Cabala CA
Am J Surg Pathol; 2017 Feb; 41(2):204-215. PubMed ID: 27879514
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with a CD15(+)CD30(-) phenotype.
Yoshizawa N; Yagi H; Horibe T; Takigawa M; Sugiura M
Eur J Dermatol; 2007; 17(5):441-2. PubMed ID: 17673391
[TBL] [Abstract][Full Text] [Related]
15. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
16. p53 oncoprotein expression in cutaneous lymphoproliferations.
Beylot-Barry M; Vergier B; DeMascarel A; Beylot C; Merlio JP
Arch Dermatol; 1995 Sep; 131(9):1019-24. PubMed ID: 7661603
[TBL] [Abstract][Full Text] [Related]
17. Differential NFATc1 Expression in Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoma and Other Forms of Cutaneous T-Cell Lymphoma and Pseudolymphoma.
Magro CM; Momtahen S
Am J Dermatopathol; 2017 Feb; 39(2):95-103. PubMed ID: 27097342
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous lymphomas: an update. Part 1: T-cell and natural killer/t-cell lymphomas and related conditions.
Kempf W; Kazakov DV; Kerl K
Am J Dermatopathol; 2014 Feb; 36(2):105-23. PubMed ID: 24556897
[TBL] [Abstract][Full Text] [Related]
20. Satb1: Restraining PD1 and T Cell Exhaustion.
Nixon BG; Li MO
Immunity; 2017 Jan; 46(1):3-5. PubMed ID: 28099863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
